START conducts the largest Phase I clinical trials program for new anticancer drugs and operates a global network of sites in San Antonio, Texas, Madrid, Spain and Shanghai, China. START in San Antoni...
START conducts the largest Phase I clinical trials program for new anticancer drugs and operates a global network of sites in San Antonio, Texas, Madrid, Spain and Shanghai, China. START in San Antonio is located at the START Center for Cancer Care. The mission of START is to accelerate the development of new anticancer drugs with the purpose of improving quality of life and survival for patients with cancer. In 2008, START expanded globally with the launch of START Madrid and was followed in 2011 with the opening of START Shanghai. The goal this global network is to keep the development of anticancer agents operating 24 hours a day and to make the newest, most innovative Phase I clinical trials available in strategic locations across the globe where patients suffering with end stage cancer presently have limited access to early phase drugs. START consists of a team of the world's most highly trained physicians and a staff with extensive experience in Phase I clinical trials research. Because of the work of scientists like those at START, real progress is being made against cancer. Through the hard work of these physicians and the continuing advances in technology we are able to improve the tools to understand, detect, and diagnose cancer. Today, people with cancer are living longer than ever before with a better quality of life.
Founded Year
2007
Organization Website
startthecure.com
Organization Languages
English
Current Technologies
nginx
google analytics
Job Functions
Entrepreneurship
Finance
Education
Operations
medical practice
phase i clinical trials
cancer research
preclinical cancer research
research
hospital & health care
Rebecca Arcos's Work History and Education
START- South Texas Accelerated Research Therapeutics
Associate Director, Regulatory Affairs
Present
Colleagues at
Start South Texas Accelerated Research Therapeutics